Clovis’ Rubraca, the drug showing significant benefits for all ovarian cancer patients in a maintenance setting – and better results than its rivals.
A look ahead at some of the most eye-catching data and trends at ESMO 2017
pharmaphorum media and Symplur, LLC launch Conference360 Report to help pharma and other stakeholders understand social media conversations around medical congresses
QuintilesIMS’s Cristina Oliva talks to pharmaphorum about her personal highlights from this year’s congress.
Roche’s PD-L1 drug has generated impressive data in second line lung cancer
Despite Keytruda’s overwhelming victory, it’s not over yet in NSCLC